{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"12.670","rs_stock_flag":false,"fiscal_year_end":"31 Dec 2024","hist_closedate":"25 Sep 2025","replication_method":null,"amt_os":"971,195,697","primaryexch":"HKEX","ric":"9966.HK","product_subtype":null,"db_updatetime":"26 Sep 2025 18:38","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.1729,"inline_upper_strike_price":"","sedol":"BL6WGG4","am":"36.47","iv":"","ew_strike":"","as":"12.400","geographic_focus":null,"incorpin":"Cayman Islands","etp_baseCur":null,"ew_amt_os":"","bd":"12.270","registrar":"Computershare Hong Kong Investor Services Ltd.","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"1,000","update_time":"2025-09-26 10:38:37.0","lo52":"2.580","shares_issued_date":"31 Aug 2025","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"Xu Ting","underlying_ric":"9966.HK","hi52":"13.390","issuer_name":"Alphamab Oncology - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"26 Sep 2025 16:08","aum_date":"","lo":"12.080","mkt_cap":"11.91","f_aum_hkd":null,"ew_sub_per_to":"","ls":"12.270","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"Healthcare - Pharmaceuticals & Biotechnology","ew_desc":null,"inception_date":"","nc":"-0.390","aum":"","issued_shares_class_B":null,"vo":"2.94","secondary_listing_flag":false,"listing_date":"12 Dec 2019","issued_shares_class_A":null,"as_at_label":"as at","ew_amt_os_dat":"","nm":"Alphamab Oncology - B","nm_s":"ALPHAMAB-B","sym":"9966","inline_lower_strike_price":"","listing_category":"Primary Listing","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"Alphamab Oncology is an investment holding company principally engaged in research and development, manufacturing and commercialisation of biologics of oncology. The Company’s highly differentiated in-house pipeline consists of ADCs, monoclonal antibodies and bispecific antibodies in staggered development status in oncology. The Company’s drug candidates include KN046 (PD-L1/CTLA-4 bispecific antibody), KN026 (HER2/HER2 bispecific antibody), KN035 (SubQ PD-L1), JSKN003 (HER2 biparatopic ADC), and others, used for indications such as 1L sq NSCLC, 1L HER2+ BC, advanced solid tumors, and HER2-expressing solid tumors.","op":"12.600","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"Biotechnology","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"Room 1901, 19/F<br/>Lee Garden One<br/>33 Hysan Avenue<br/>Causeway Bay, Hong Kong","pc":"-3.08","days_to_expiry":null,"underlying_code":null,"pe":"67.01","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"12.660","isin":"KYG0330A1013","moneyness":""}},"qid":"1758890255827"}
